UMass Chan Affiliations
Department of NeurologyDocument Type
Journal ArticlePublication Date
2003-01-02Keywords
Acute DiseaseAnimals
Fibrinolytic Agents
Humans
Neuroprotective Agents
Stroke
Nervous System Diseases
Neurology
Metadata
Show full item recordAbstract
The development of additional acute stroke therapies to complement and supplement intravenous recombinant tissue-type plasminogen activator within the first 3 hours after stroke onset remains an important and pressing need. Much has been learned about the presumed target of acute stroke therapy, the ischemic penumbra, and clinically available imaging modalities such as magnetic resonance imaging and computed tomography hold great promise for at least partially identifying this region of potentially salvageable ischemic tissue. Understanding the biology of ischemia-related cell injury has also evolved rapidly. New treatment approaches to improve outcome after focal brain ischemia will likely be derived by looking at naturally occurring adaptive mechanisms such as those related to ischemic preconditioning and hibernation. Many clinical trials previously performed with a variety of neuroprotective and thrombolytic drugs provide many lessons that will help to guide future acute stroke therapy trials and enhance the likelihood of success in future trials. Combining knowledge from these three areas provides optimism that additional acute stroke therapies can be developed to maximize beneficial functional outcome in the greatest proportion of acute stroke patients possible.Source
Ann Neurol. 2003 Jan;53(1):10-20. Link to article on publisher's siteDOI
10.1002/ana.10407Permanent Link to this Item
http://hdl.handle.net/20.500.14038/37612PubMed ID
12509843Related Resources
Link to article in PubMedae974a485f413a2113503eed53cd6c53
10.1002/ana.10407